Kornimate/medical-research-clean huggingface dataset:
blood flow restriction in improving muscle strength of patients with hemophilic ankle arthropathy

Conditions: Hemophilia

Summary: background. the main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). this sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy. objective. to assess the safety and effectiveness of an intervention through blood flow restriction, regarding the frequency of bleeding and the improvement in muscle activation and strength, range of motion, stability, joint pain, joint status and the perception of quality of life in patients with hemophilic ankle arthropathy. study design. randomized, multicenter, single-blind clinical study. method. 32 patients with hemophilia a and b will be recruited in this study. patients will be recruited in 4 regions of spain. the dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale and pressure algometer), quality of life (sf-36 scale), joint status (hemophilia joint health score scale), strength (dynamometer) and muscle activation (surface electromyograph), range of motion (goniometer) and stability (the single leg stance test). three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks. expected results. observe the safety of blood flow restriction in hemophilia patients. to analyze the efficacy of blood flow restriction in improving muscle strength and activation, range of motion, chronic pain, stabilit, and the perception of quality of life in patients with hemophilic ankle arthropathy.


Eligibility criteria:
inclusion criteria: * patients diagnosed with hemophilia a and b * people with a medical diagnosis of hemophilic ankle arthropathy * patients over 18 years of age * paceinets in prophylactic or on-demand treatment regimen with fviii/fix concentrates. * failure to sign the informed consent document exclusion criteria: * patients with neurological or cognitive alterations that prevent understanding of the questionnaires * amputee patients, epileptics or patients with severe vision problems * patients who are receiving physiotherapy treatment at the time of the study

Keywords: hemophilia blood flow restriction physiotherapy muscular strength muscle activation range of motion chronic pain stability
monitoring the peripheral intravenous infusion site for infiltration and extravasation

Conditions: Infiltration; Extravasation; IV Infiltration; IV Extravasation; Extravasation of Diagnostic and Therapeutic Materials

Summary: the purpose of this study to to monitor the peripheral intravenous (piv) site on subjects receiving continuous iv fluids for infiltration and extravasation events. infiltration is an indication that the piv is leaking fluids outside of the vascular system. the study hypothesis is to demonstrate that changes in the optical signals of the non-invasive monitoring medical device will detect infiltration and extravasation events.


Eligibility criteria:
inclusion criteria: * signed consent * patient age under 12 * piv with continuous fluids exclusion criteria: * no consent * patient age over 12 * piv fluids not continuous

Keywords: infiltration extravasation leaking piv infiltration iv infiltration optical detection of infiltration optical monitoring
factors predictive of adverse postoperative outcomes in children undergoing tonsillectomy

Conditions: Tonsillectomy Postoperative Adverse Events

Summary: the purposes of the study are to identify 1) the patient (demographic and clinical) and health care system factors predictive of immediate and late postoperative adverse outcomes in children undergoing tonsillectomy. 2) evaluate the preoperative use of the sleep questionnaire to identify children at risk for immediate and late postoperative adverse outcomes in children undergoing tonsillectomy.

currently, children are scheduled to go home or stay in the hospital depending on expert consensus and institutional guidelines. the investigators preliminary experience (dr. sadhasivam pi: irb no. 2008-0848) with the pharmocogenetic study, studying the phenotypic and genotypic influences of pain and use of opioids in patients undergoing tonsillectomy indicates that a significant number of patients scheduled as outpatients experience prolonged recovery phases in the pacu, some of whom are admitted or re-admitted following discharge. the identification of those factors that are, predictive of adverse events in tonsillectomy patients and the development of a prototype prediction model in this single-center study to support clinical decision-making. the rationale of this project is that developing a model to predict postoperative adverse events will not only lead to improved clinical outcomes and enhance patient safety, but also reduce family psychosocial distress associated with unanticipated hospital visits or re-admission, while reducing the burden on the health care system.

Eligibility criteria:
inclusion criteria: * children 0-17 years of age * children scheduled for tonsillectomy or adeno-tonsillectomy * asa i, ii, or iii exclusion criteria: * asa iv and v

Keywords: outcomes quality improvement patient safety pacu complications adverse events respiratory arrest pain ponv age neonate infant child ambulatory inpatient general anesthesia otolaryngology tonsillectomy obstructive sleep apnea
heel warming before capillary blood sampling

Conditions: Blood Specimen Collection

Summary: capillary blood sampling from the heel is often used in the treatment of infants admitted to neonatal intensive care (nicu). in danish nicus a heated blanket, a heated gel pad or a disposable glove with warm water are the methods most often used. the purpose of this randomized controlled study is to investigate which of the mentioned heating methods ensures the best quality of the blood sample and provides the most gentle blood sampling for the infant.

some infants experience a difficult and painful blood sampling which can lead to bruised or swollen heels and a blood sample of poor quality. to minimize the risk of that, the infant's heel is heated before the procedure as described in standard gp42-a6 from the clinical and laboratory standards institute. however, no consensus exists on which heating method to use. the aim of this study is to compare three different heating methods in terms of which method can help reduce pain experienced by infants as well as increase the quality of the blood samples. infants (postmenstrual age ≥ 28 + 0) admitted to the nicu, kolding hospital and having a blood sample taken by a biomedical laboratory scientist are invited to participate. a parental informed concent must be signed by both parents before participation. infants are randomized to one of the three heating methods: glove, blanket or gel pad. the following blood sampling procedure is closely monitored to register data corresponding to the five outcome measures. furthermore the infants personal data, location of the infant during the procedure, surface temperature of the heel before and after heating, volume of sampled blood, sign of bruises and swelling as well as hematocrit are registered. data registration, web-based block randomization, data storage and statistical analysis are supported by open (open patient data explorative network, university of southern denmark). the study is registered as public research at the region of southern denmark (journal no. 20/1316) and is approved by the regional committees on health research ethics for southern denmark (id s-20200082).

Eligibility criteria:
inclusion criteria: * pma (postmenstrual age) ≥ 28+0 * blood sampling performed by a biomedical laboratory scientist exclusion criteria: * ga (gestational age) ≥ 44+0 * weight \> 6000 g * coagulation related disorder * severe illness/disorder * heel is bruised or swollen * parents not understanding written danish language

Keywords: blood specimen collection phlebotomy infant, newborn heating heel pain
molecular signatures in inflammatory skin disease

Conditions: Atopic Dermatitis; Psoriasis

Summary: this pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and disease control by integrating and modelling data across multiple cellular levels and time following specific blockade of single pathophysiological factors through use of licensed biologics during routine care as systems biology challenge. to this end, ultra-deep phenotyping and prospective molecular characterization in short time-intervals and different disease equilibrium states will be carried out in targeted small sets of patients. the different layers and types of clinical and molecular information will then be integrated (integrative personal omics profiling ipop) for generating insights into disease pathways and for extraction of molecular signatures that correspond to clinical severity scores. it will provide a good starting point for planning future trials aimed at identifying biological patterns useful for guiding targeted treatment.

this is an exploratory study with the aim to identify molecular profiles and signatures in skin and blood that correlate with inflammatory skin disease, disease activity and disease progression, and that are associated with possible disease subtypes/endotypes. primary target variables are differentially expressed genes (alone or in combination), secondary target variables are genetic, immunological and microbiological signatures. influencing variables of interest include age of manifestation, disease duration, disease activity/severity, disease progression, comorbidities and therapy/treatment. obtained biomaterial will be used for molecular profiling including dna/rna sequencing, elisa, mass spectrometry, flow cytometry to identify markers and/or signatures that can correlate with individual disease courses.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with the protocol * diagnosis of chronic psoriasis or atopic dermatitis * pasi score ≥ 10 or easi score ≥ 16 * investigator global assessment (iga) ≥ 3 * subject receives systemic therapy within routine care (in-label use of biologics) exclusion criteria: * subject is unable to provide written informed consent or comply with the protocol. * having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks before the baseline visit. * treatment of selected skin areas to be examined with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit.
very-low-density-lipoprotein triglyceride (vldl-tg) uptake in visceral fat

Conditions: Healthy; Obesity

Summary: purpose: to investigate the uptake of vldl-tg in visceral fat in lean and overweight individuals


Eligibility criteria:
inclusion criteria: * healthy * age: 20-50 years * premenopausal exclusion criteria: * smoking * alcohol abuse * use of medications

Keywords: obesity lipid metabolism vldl
patient reported outcome post radiation therapy or chemoradiotherapy patient care in patients with oropharyngeal cancer

Conditions: Oropharyngeal Carcinoma

Summary: this study examines patient reported outcomes post radiation therapy or chemoradiotherapy patient care in patients with oropharyngeal cancer. this study may help researchers learn about the symptoms that patients with oropharyngeal cancer have after completing radiation therapy.

primary objective: i. to provide evidence of clinically relevant symptoms for integrating into a user-friendly, automated pathway for real-time tracking and management of symptoms during post radiation therapy (rt)/chemoradiation (crt) for oropharyngeal cancer (opc). outline: patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.

Eligibility criteria:
inclusion criteria: * patients who were seen for new patient evaluation at clinics and hnc centers at md anderson cancer center * adult patients with opc (\> 18 years old) who have been enrolled under pa14-0947
enhance of language learning with neurostimulation

Conditions: Stroke; Aphasia; Aging

Summary: the purpose of this study is to test the effect of transcranial direct current stimulation over the motor cortex of the language dominant hemisphere on language learning in healthy subjects and stroke patients with aphasia. we hypothesize that anodal stimulation enhances the learning of action words compared to sham and cathodal stimulation.

the motor cortex is involved at different levels of language processing. it has been demonstrated that the perception of action words activates motor representations in the language-dominant hemisphere. however, it is not known whether modulation of excitability has an effect on learning new action words. thus, we hypothesize that transcranial direct current stimulation over the motor cortex of the language-dominant hemiphere modulates the acquisition of new action words. the results bear the potential to design new rehabilitative strategies in stroke patients with aphasia. the motor cortex might offer an access to the language network that can be used for interventional approaches such as neurostimulation.

Eligibility criteria:
inclusion criteria: * age \>18 and \< 86 years * contractual capability * ischemic stroke excluding motor cortex (stroke patients) * minimum time since stroke 9 months * aphasia (stroke patients) * severe aphasia that impedes understanding of instructions (stroke patients) exclusion criteria: * sever head trauma in the past * seizures * pace maker * metal implants in the head/neck region * severe comorbidity, especially neurologic and psychiatric diseases * intake of illegal drugs * mini mental state examination score \< 27 * neuroactive substances, e.g. antidepressants * pregnancy

Keywords: stroke aphasia aging language learning
balloon prophylaxis of aneurysmal vasospasm

Conditions: Aneurysm; Vasospasm

Summary: the purpose of this study is to determine if early transluminal ballooning of the major cerebral arteries prevents severe vasospasm and improves neurological outcome in patients with fisher grade iii aneurysmal subarachnoid hemorrhage.

aneurysmal subarachnoid hemorrhage (sah) afflicts over 30,000 patients a year in the united states. fifteen percent of those who survive the initial bleeding die or suffer disabilities because of delayed ischemic deficit (stroke) due to vasospasm. vasospasm is a condition in which the arteries in the brain constrict, not allowing sufficient blood flow and oxygenation. research on the pharmacological prevention and treatment of vasospasm has resulted in only minimal improvement for this problem. transluminal ballooning is a procedure that opens blood vessels, allowing blood flow and oxygen to get to the brain more easily. researchers believe that this dilation of the blood vessels lasts for at least 7 days. this procedure is used to treat severe vasospasm although it is not commonly used to prevent vasospasm. the purpose of this trial is to find out if this procedure, performed immediately after the aneurysm is secured, prevents spasm in the brain and improves patient outcome. eligible sah patients whose aneurysm has been repaired by neurosurgical or endovascular procedure and who are enrolled in the study will be randomized to receive either the prophylactic transluminal ballooning procedure or to receive standard care, which includes currently existing therapies for the treatment of vasospasm. participants will be asked to return for follow-up examinations at 3 and 6 months to evaluate recovery using a standardized outcome scale.

Eligibility criteria:
inclusion criteria: * fisher grade iii hemorrhage * documented ruptured cerebral aneurysm via angiography, ct angiogram or any other acceptable neuroradiologic means * ruptured aneurysm(s) secured * ballooning available \< 96 hours post sah exclusion criteria: * vasospasm prior to randomization * interventionalist unavailable * patient outside the 96 hour window for ballooning * enrolled in competing trial * unsecured aneurysms (symptomatic or asymptomatic) that are in the location where the ballooning procedure would occur * medical conditions known that would effect mortality / morbidity * severe cerebrovascular atherosclerosis * \> 16 years old.

Keywords: aneurysm vasospasm subarachnoid hemorrhage transluminal ballooning
an exploratory clinical trial evaluating the tolerability and efficacy of kh906 in patients with corneal neovascularization

Conditions: Corneal Neovascularization

Summary: the first stage of this study will evaluates the tolerability of different concentrations of conbercept eye drop to patients with corneal neovascularization. the second stage of this study will evaluate the effectiveness of conbercept eye drop initially.


Eligibility criteria:
inclusion criteria: * signed the informed consent form, volunteered to participate in the trial and followed up according to the protocol. * ages from 18 to 75,male or female. * superficial or deep neovascularization induced by trauma/chemical burn/inflammation/corneal transplantation. exclusion criteria: * subjects who had significant defect in the corneal epithelium. * study eye had been injected of anti-vegf drugs within 3 months before screening * study eye was performed surgery (except keratoplasty) within 3 months prior screening, or eye surgery was planned during this trial period. * oral glucocorticoid administration within 1 month prior screening (except for duration less than 7 days) * systemic use of anti-vegf drugs within 45 days prior to screening. * have history of abnormal coagulation, such as end-stage liver disease, or are taking anticoagulants（except aspirin）. * uncontrolled clinical problems such as canner etc.. * unable or unwilling to use effective contraception. * positive blood tests for pregnancy (female subjects) * participated in drug clinical trials within 3 months before the first administration. * the researchers think the participants were not suitable for this trail.
apnealink air home sleep testing (hst) device validation study

Conditions: Sleep-disordered Breathing

Summary: this study compares the diagnostic capability of a home sleep apnea testing device to polysomnography.

the current gold standard for sleep disordered breathing (sdb) diagnosis is in-laboratory polysomnography (psg). a barrier of acceptance of home sleep apnea testing (hsat) devices as a diagnostic test is their inability to accurately measure total sleep time (tst). a novel algorithm developed by resmed, ltd. allows the al device to accurately calculate tst, however, this algorithm has not yet been validated. the apnealink air (al) device is a type iii hsat device. the device is capable of recording up to four channels of data including: flow and snore via a nasal cannula attached to a pressure transducer, a respiratory effort belt, a pulse oximeter to measure pulse and oxygen saturation, and an actigraphy monitor to measure tst along with flow. the al device has been validated against psg for ahi, and cheyne-stoke respiration detection . further validation of the effort belt is necessary to determine the accuracy of the al ability to differentiate between obstructive and central apneic events.

Eligibility criteria:
inclusion criteria: * participant is 18 years of age or older * participant is willing to provide informed consent * participant is willing to participate in all study related procedures exclusion criteria: * unable to cease positive airway pressure (pap) therapy during psg (if currently using) * requires use of oxygen therapy during sleep * diagnosis of uncontrolled clinically relevant sleep disorder (e.g., untreated insomnia or restless leg syndrome) * pregnant * participant is unsuitable to participate in the study in the opinion of the investigator
study to determine if taking otc non-steroidal anti-inflammatory affects eye pressure in patients using glaucoma drops

Conditions: Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to determine if taking an over the counter non-steroidal anti-inflammatory(ibuprofen)has an effect on eye pressure in patients using brimonidine(alphagan)and latanoprost(xalatan) eye drops.

topical iop-lowering therapy has the advantage of providing a drug level directly to the end organ with very little or no systemic absorption thereby reducing side effect potential. there is very little information in the ophthalmic literature regarding potential drug interactions between topical iop-lowering medications and other medications taken orally for other medical reasons. patients will be randomized to either latanoprost or brimonidine. patients in both groups will be randomized to either placebo or ibuprofen for the first 14 days and then crossed over to the other treatment for 14 days.

Eligibility criteria:
inclusion criteria: * patients with bilateral or unilateral primary open angle glaucoma or ocular hypertension * an iop in each eye of greater than 22mm hg after washout of iop lowering medications * no worse than 20/200 best corrected visual acuity * normal appearing or non-occludable anterior chamber angles * discontinuation of current poag or oh medications before participation in the study. * written informed consent exclusion criteria: * use of any other ocular medications * previous ocular surgery or laser therapy within the last three months. * systemic treatment with any adrenergic agonist or antagonist, corticosteroid or nonsteroidal anti-inflammatory agents(low dose apsirin will be accepted if dose remains the same for entire study period). * an age of less than 21,of child bearing age and currently pregnant, considering pregnancy or a nursing mother. * a history of medical noncompliance or unreliability. * presence of uncontrolled hypertension, cardiac arrhythmia, cerebrovascular accident, nasal polyps, bleeding diathesis, peptic ulcer disease, gastritis or known intolerance, contraindication or allergy to any drugs used in the study. * lactose intolerance.

Keywords: glaucoma ocular hypertension xalatan alpahgan ibuprofen non-steroidal anti-inflammatory brimonidine latanoprost eye pressure intra-ocular pressure